Thierry Piéton compensation by year
Medtronic Summary Compensation Table · all 2 fiscal years held| Component | FY2025 | FY2026 |
|---|---|---|
| Salary | $138,517 | $849,648 |
| Bonus | $0 | $2,000,000 |
| Stock awards | $4,190,625 | $3,170,470 |
| Option awards | $600,056 | $1,200,139 |
| Non-equity incentive | $141,975 | $963,050 |
| Pension and deferred compensation | $0 | $0 |
| All other | $141,274 | $404,079 |
| Total | $5,212,448 | $8,587,387 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Medtronic plc DEF 14A filed August 17, 2026, accession 0001613103-26-000010, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Medtronic plc filed document, accession 0001613103-26-000010. Every figure is read from that document and cited to the page and table it appears in. Filed August 17, 2026.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 22,251 | $1,853,953 | — |
| RSU | 18,383 | $1,531,672 | — |
| PSU | 11,029 | $918,936 | — |
| RSU | 8,901 | $741,631 | — |
| RSU | 4,412 | $367,608 | — |
| Option | 61,338 | — | $91.97 |
| Option | 22,181 | — | $94.30 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Medtronic plc's FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Medtronic discloses, by trigger · FY2026| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $3,570,000 | $1,531,597 | $20,000 | $5,121,597 |
| Change in control and involuntary termination | $6,402,200 | $5,413,594 | $548,459 | $12,364,253 |
Per the Potential Payments Upon Termination or Change in Control table in Medtronic plc's FY2026 proxy. Estimates as the company printed them; a dash means it printed no figure.
Medtronic’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Geoffrey Martha | Chairman and Chief Executive Officer | $22,940,252 |
| Thierry Piéton · this page | Executive Vice President and Chief Financial Officer | $8,587,387 |
| Brett Wall | Former Executive Vice President and President, Neuroscience Portfolio | $6,921,425 |
| Michael Marinaro | Executive Vice President and President, Medical Surgical Portfolio and Americas | $6,832,836 |
| Michelle Quinn | Executive Vice President, General Counsel and Secretary | $6,719,170 |
Thierry Piéton's compensation dossier, Medtronic
You have read Thierry Piéton's totals and holdings. The dossier adds each equity grant Medtronic disclosed for Thierry Piéton and Medtronic's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Medtronic compensation record
free company briefThis page is one person within Medtronic's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Medtronic proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Medtronic's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Medtronic's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order MDT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.